GlassScriptPhysician profile
Vindya Boelke
NPI 1053731885
$2,949.15
in general payments reported to CMS, 2019-2025
27 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $499 · 2021: $108 · 2022: $226 · 2023: $542 · 2024: $455 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.23 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $793.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $414.55 | 2020-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $223.14 | 2019-2025 | Synthroid, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $177.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.84 | 2019-2025 | Jardiance |
| Mannkind Corporation | $149.91 | 2019-2025 | Afrezza |
| Insulet Corporation | $98.90 | 2022-2025 | Omnipod |
| Medtronic Minimed, INC. | $97.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.66 | 2025 | |
| Lilly USA, LLC | $85.57 | 2022-2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $80.23 | 2019-2024 | Tirosint, Licart |
| Horizon Therapeutics Plc | $76.09 | 2021-2023 | Tepezza |
| Genzyme Corporation | $72.00 | 2020 | |
| Medtronic, INC. | $71.23 | 2021-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $69.84 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $47.35 | 2025 | |
| Dexcom, INC. | $47.15 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $30.75 | 2020-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $28.61 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $27.46 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $23.63 | 2023 | Evkeeza |
| Pfizer INC. | $19.75 | 2022 | |
| Tandem Diabetes Care, INC. | $18.00 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $16.33 | 2024 | Qutenza |
| Lifescan, INC. | $15.88 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2021 | |
| Beta Bionics, INC. | $3.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vindya Boelke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.